Blog
RSS FeedPosted by Michael Wonder on 10 Oct 2023
Lynparza (olaparib) accepted for use in Scotland as adjuvant treatment for patients with germline BRCA mutated HER2 negative high risk early breast cancer
9 October 2023 - First and only approved medicine in Scotland which targets germline (hereditary) BRCA mutations in early breast cancer ...
Posted by Michael Wonder on 13 Mar 2023
SMC - March 2023 decisions
13 March 2023 - The SMC which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 14 Feb 2023
Scotland becomes first part of UK to approve new cervical cancer drug
13 February 2023 - The SMC has approved the use of the drug pembrolizumab – which is also known as ...
Posted by Michael Wonder on 19 Jan 2023
Scottish Medicines Consortium recommends Merck’s Tepmetko
18 January 2023 - Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients ...
Posted by Michael Wonder on 16 Jan 2023
SMC - January 2023 decisions
16 January 2023 - The Scottish Medicines Consortium, which advises on newly-licensed medicines for use by NHSScotland, has today published ...
Posted by Michael Wonder on 13 Sep 2022
Prostate cancer symptoms as new treatment given green light in Scotland
13 September 2022 - A new treatment for advanced prostate cancer has been approved for use in Scotland, giving medical ...
Posted by Michael Wonder on 10 Mar 2022
SMC accepts Lumykras (sotorasib) for locally advanced or metastatic non-small cell lung cancer for use on an interim basis by NHS Scotland
7 March 2022 - Sotorasib Is indicated as monotherapy for the treatment of adult patients with KRAS G12C mutated locally advanced ...
Posted by Michael Wonder on 09 Mar 2022
SMC approval welcome news for breast cancer patients
9 March 2022 - Trodelvy is accepted for use in metastatic triple negative breast cancer. patients who have already received two ...
Posted by Michael Wonder on 24 Jan 2022
Breast cancer patients in Scotland are set to receive tumour blasting wonder drug that starts working in weeks - sparking hopes of a wider rollout for NHS patients across the rest of the UK
23 January 2022 - A breast cancer drug that can melt away tumours in weeks has been given the green ...
Posted by Michael Wonder on 14 Dec 2021
SMC approves first immunotherapy combination for advanced bowel cancer patients with rare mutation
14 December 2021 - Nivolumab plus ipilmumab has been accepted as a treatment option for adult patients by NHS Scotland ...
Posted by Michael Wonder on 11 Nov 2021
Three cancer drugs approved for NHS use in Scotland
10 November 2021 - Three new cancer drugs have been given the go-ahead by the SMC for routine use in ...
Posted by Michael Wonder on 13 Oct 2021
SMC accepts Cabometyx/Opdivo combo for advanced kidney cancer patients
13 October 2021 - The SMC has recommended Cabometyx (cabozantinib) plus Opdivo (nivolumab) for use by via NHS Scotland for ...
Posted by Michael Wonder on 09 Aug 2021
Scotland backs Bavencio for bladder cancer after NICE says no
9 August 2021 - Patients with bladder cancer in Scotland will be the first in the UK to claim access ...
Posted by Michael Wonder on 09 Aug 2021
SMC - August 2021 decisions
9 August 2021 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 13 Jul 2021
Tecentriq, Kesimpta lead latest SMC decisions
13 July 2021 - The SMC has accepted three new medicines for use by NHS Scotland and rejected one in its ...